Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexmedetomidine.

D B Coursin1, D B Coursin, G A Maccioli

  • 1Department of Anesthesiology, University of Wisconsin, Madison, WI 53792-3272, USA. dcoursin@facstaff.wisc.edu

Current Opinion in Critical Care
|September 26, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy vs efficiency using high flow nasal oxygen in peri-intubation oxygenation of gravid women.

International journal of obstetric anesthesia·2020
Same author

Vitamin D deficiency in anesthesia department caregivers at the end of winter.

Acta anaesthesiologica Scandinavica·2014
Same author

Glycaemic control in the perioperative period.

British journal of anaesthesia·2013
Same author

Regional distribution of pyridoxal-5'-phosphate in developing and mature brains and its depletion in pyridoxine deficiency.

Neurochemical research·2013
Same author

Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit.

Critical care clinics·2002
Same author

The anesthesiologist in critical care medicine: past, present, and future.

Anesthesiology·2001

Dexmedetomidine, an alpha2-agonist, offers improved sedation and analgesia in intensive care units. While effective for short-term adult ICU use, further research is needed for broader applications and long-term safety.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Intensive Care Medicine

Background:

  • Sedative-hypnotic and analgesic agents are crucial for patient comfort and safety in healthcare settings.
  • Existing agents like benzodiazepines, propofol, and narcotics have limitations in modern intensive care.
  • Dexmedetomidine, an alpha2-agonist, was developed to address the need for an improved sedative and analgesic agent.

Purpose of the Study:

  • To evaluate dexmedetomidine as a novel sedative and analgesic agent for intensive care unit (ICU) patients.
  • To explore the unique pharmacologic profile of dexmedetomidine, including its receptor binding affinity and duration of action.
  • To assess the safety and efficacy of dexmedetomidine infusion in various patient populations and for different durations of use.

Main Methods:

Related Experiment Videos

  • Dexmedetomidine stimulates alpha2-adrenergic receptors in the locus ceruleus for sedation and the spinal cord for analgesia.
  • The drug exhibits sympatholysis through central and peripheral mechanisms.
  • Clinical experience primarily involves surgical patients, with initial evaluations noting potential hemodynamic side effects (bradycardia, hypertension, hypotension).

Main Results:

  • Dexmedetomidine was approved in late 1999 for adult ICU sedation infusions lasting less than 24 hours.
  • Slower administration (20-minute bolus) minimizes adverse hemodynamic effects like decreased heart rate and blood pressure.
  • Continuous infusion provides unique sedation (arousable patients), spares analgesics, and minimally depresses respiratory drive.

Conclusions:

  • Dexmedetomidine offers a promising alternative for short-term sedation and analgesia in adult ICUs, particularly for surgical patients.
  • Careful patient selection and controlled infusion rates are essential to manage potential hemodynamic effects.
  • Further research is required to establish its safety and effectiveness for medical ICU patients and long-term use (>24 hours), especially in those with complex end-organ dysfunction.